Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of intravenous single ascending doses of IM-250 in healthy volunteers.

2025-523146-27-00 Protocol IM-104 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 26 May 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol IM-104

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 30
Countries 1
Sites 1

Herpes simplex virus encephalitis

Key facts

Sponsor
Fuics Development Limited
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
26 May 2026 → ongoing
Decision date (initial)
2025-11-18
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Herpes simplex virus encephalitis

VersionLevelCodeTermSystem organ class
27.1 PT 10019953 Herpes simplex encephalitis 100000004862

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Fuics Development Limited

Sponsor organisation
Fuics Development Limited
Address
Leontiou Machaira 58
City
Limassol
Postcode
3025
Country
Cyprus

Scientific contact point

Organisation
Fuics Development Limited
Contact name
Company management

Public contact point

Organisation
Fuics Development Limited
Contact name
Company management

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ongoing, recruiting 30 1
Rest of world 0

Investigational sites

Bulgaria

1 site · Ongoing, recruiting
Diagnostics And Consultation Center Convex Ltd.
Clinical Pharmacology, Ulitsa Sinanishko Ezero 11a, 1680, Sofiya

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2026-05-26 2026-06-03

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-08-05 Bulgaria Acceptable
2025-11-17
2025-11-18
2 SUBSTANTIAL MODIFICATION SM-1 2026-01-09 Bulgaria Acceptable
2026-01-27
2026-01-28
3 SUBSTANTIAL MODIFICATION SM-2 2026-03-09 Bulgaria Acceptable
2026-05-15
2026-05-18
4 NON SUBSTANTIAL MODIFICATION NSM-1 2026-06-08 Bulgaria Acceptable
2026-05-15
2026-06-08
5 NON SUBSTANTIAL MODIFICATION NSM-2 2026-06-16 Bulgaria Acceptable
2026-05-15
2026-06-16
6 NON SUBSTANTIAL MODIFICATION NSM-3 2026-06-25 Bulgaria Acceptable
2026-05-15
2026-06-25